@FierceMedDev: More legal action is in the mix against Intuitive over its robotic surgical device. Story | Follow @FierceMedDev
@MarkHFierce: The latest FierceDiagnostics is ready for you, featuring details on an IPO, cancer Dx and Alzheimer's biomarkers. Report | Follow @MarkHFierce
@MichaelGFierce: Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More from FierceDrugDelivery | Follow @MichaelGFierce
@EmilyWFierce: Tiny recorder helps parents communicate with children, and could spur brain development. Article | Follow @EmilyWFierce
> José Almeida, Covidien's ($COV) chairman, president and CEO, will become the next chairman of the AdvaMed board of directors. AdvaMed is the med tech industry's main lobbying group. Release
> The FDA granted premarket supplement approval to use Pinnacle Biologics' Optiguide device to treat non-small cell lung cancer and esophageal cancer. Release
> The FDA is proposing new rules to simplify how it classifies and reclassifies medical devices to conform to the FDA Safety and Innovation Act of 2012. Item
> Medtronic ($MDT) has disclosed to the U.S. Securities and Exchange Commission details about humanitarian sales to Syria, Cuba and Sudan. Story
> A startup has developed an armband that tracks a sick child's temperature on a smartphone. Story
> Chennai in India is becoming a hot spot for the development of new medical devices and other high-tech products and services. Story
Biotech News
@FierceBiotech: Startup scPharmaceuticals snags $16M for self-dosed injectables. Read | Follow @FierceBiotech
@JohnCFierce: Fierce readies a new weekly report on the European biotech scene. Details | Follow @JohnCFierce
@DamianFierce: Sanofi bets big on dengue with eyes on a blockbuster. More | Follow @DamianFierce
@EmilyMFierce: Most read at FierceBiotechResearch.com yesterday: Amylin diabetes drug improves learning, memory in Alzheimer's mice. Story | Follow @EmilyMFierce
> With FDA decision looming, GlaxoSmithKline nails EU OK for diabetes drug albiglutide. News
> Insmed faces another setback as lead therapy flunks PhII lung study. Story
Pharma News
@FiercePharma: Just out: today's full issue of FiercePharmaMarketing. More | Follow @FiercePharma
@TracyStaton: Anti-inflammatories rule! Top 3 best-selling drugs last year = Humira, Enbrel + Remicade. Report | Follow @TracyStaton
@EricPFierce: AmerisourceBergen global expansion continues with $100M deal for a 20% stake in Brazil's Profarma. Article | Follow @EricPFierce
@CarlyHFierce: AstraZeneca, Pfizer say direct-delivery programs can win with patients. Story | Follow @CarlyHFierce
> AstraZeneca takes control of its destiny in Japan with buyout. Article
> GlaxoSmithKline yanks European app for Tafinlar-Mekinist combo in melanoma. Story
> GlaxoSmithKline flags product tampering as wrong pills surface in alli packages. More
> Florida man threatened to poison J&J products unless it forked over cash. News
Drug Delivery News
> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. News
> Nasal spray for depression offers minimally invasive treatment option. Story
> FDA accepts Avanir's inhaled migraine treatment application. News
> Small, drug-releasing battery could dissolve completely over time. Article
> Clumps of gold nanoparticles retain heat or drugs to kill cancer cells. Story
> Alexza secures $45 million from investors based on U.S. Adasuve sales. Brief
Diagnostics News
> Ariosa Diagnostics mulls an IPO worth up to $69M. News
> Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running. Story
> CTC levels could provide a prostate cancer survival clue. Article
> Mobile app could offer inexpensive Dx in developing world. Story
> Two Alzheimer's biomarker studies spur hope for earlier-stage diagnosis. Story
> Four new biomarkers may enable an earlier stomach cancer diagnosis. Brief
Pharma Marketing News
> ASCO plans cost-benefit scorecard for cancer meds as prices grow 'unsustainable.' Story
> Pharma is a 'design industry,' expert says. So why don't all Big Pharmas have CDOs? Article
> Astellas presents The Bladder, animated pitch-organ for overactive-bladder med Myrbetriq. Story
> AstraZeneca, Pfizer say direct-delivery programs can win with patients. Article
> Great expectations: Patients think pharma owes them apps, rewards, and more. Piece
> AstraZeneca, Sanofi tap mobile providers for patient-monitoring services. Brief